Core Viewpoint - The A-share market has reached a new record, with the Shanghai Composite Index closing at 4083.67 points, marking a 1.50% increase and breaking a ten-year high since July 2015, supported by a strong performance across various sectors and increased trading volume [1][2]. Market Performance - The A-share market exhibited a comprehensive upward trend, with significant contributions from the financial, materials, and technology sectors, driven by ongoing policy benefits and accelerated industrial trends [2]. - The financial sector, particularly securities and insurance, played a crucial role in supporting the Shanghai Composite Index above 4000 points, with companies like New China Life Insurance and China Pacific Insurance reaching new highs [2]. - The cyclical sector saw notable gains due to improved supply-demand dynamics, with the metals sector, including companies like Zijin Mining, experiencing significant price increases [2]. Emerging Trends - The technology and emerging industries continued to show structural growth, particularly in the brain-computer interface sector, which has become a hot topic, with companies like Beiyikang and Weisi Medical seeing substantial stock price increases [3]. - The brain-computer interface market in China is projected to exceed 120 billion yuan by 2040, with a compound annual growth rate of approximately 26%, indicating its potential as a key growth area in the global market [3]. Trading Volume and Capital Flow - The recent market rally is characterized by a significant increase in both trading volume and price, with the Shanghai Composite Index rising nearly 7% since December 17, 2025, and total market turnover increasing from 1.8 trillion yuan to 2.8 trillion yuan [4]. - Various funding sources, including foreign capital and margin trading, have contributed to this volume increase, with margin trading balances reaching a historical high of 25,606.48 billion yuan [4]. Institutional Outlook - Institutions are generally optimistic about the A-share market's future performance, attributing the current rally to a confluence of favorable policies, capital influx, and strong fundamentals [6]. - Analysts suggest that the ongoing "spring rally" has room for further development, with a focus on sectors benefiting from AI investments and global manufacturing recovery, such as industrial resources and equipment exports [7].

Group 1: Non-Bank Financial Sector - The insurance sector is expected to enter a "golden development cycle" as the proportion of insurance in residents' financial management continues to rise, driven by the dual advantages of savings and protection [3][8][9] - The transformation of dividend insurance is enhancing product attractiveness, with demand for pension and health protection steadily increasing, and the supply of large-denomination certificates of deposit shrinking [8][10] - By 2026, new individual insurance policies are anticipated to stabilize and grow, benefiting from the performance of leading insurance companies and the improvement in new business value (NBV) growth [3][8][10] Group 2: Medical Sector - Brain-Computer Interface (BCI) - The brain-computer interface (BCI) technology is undergoing rapid transformation, with various technical paths available, including invasive, semi-invasive, and non-invasive methods, each with its own advantages [4][12][15] - The Chinese BCI market is projected to reach approximately 1.73 billion yuan in 2023, accounting for 12.5% of the global market, with significant growth potential in medical applications [14][15] - Policy support is crucial for the BCI industry, with initiatives aimed at establishing standards and payment systems to facilitate clinical applications and reduce costs [14][15] Group 3: Media Sector - Gaming Companies - The gaming company is demonstrating confidence through a share buyback of up to 400 million HKD, with expectations for revenue growth driven by upcoming game launches and seasonal events [5][18][21] - The company has adjusted its net profit forecasts for 2025-2027, reflecting a focus on game reserves and the growth potential of its TapTap and ADN businesses [5][18] - The upcoming high-profile game releases and improvements in advertising algorithms are expected to enhance user engagement and revenue growth for TapTap [18][21] Group 4: Sports Sector - Racing Industry - The racing company is positioned as a leader in the racing services sector, with a diversified sports layout expected to accelerate growth, supported by its experience in event operations and venue management [6][22][23] - The company is set to leverage its unique international racing venues, particularly in Hainan, to capitalize on the growing popularity of motorsports in China [22][23] - The expansion into golf and other sports is anticipated to create a second growth curve, aligning with national policies promoting sports development [22][24]

新京报贝壳财经讯1月6日，爱朋医疗（300753）公告，公司股票交易价格于2026年1月5日、2026年1月6 日连续两个交易日内收盘价格涨幅偏离值累计超过30%。公司前期披露的信息不存在需要更正、补充之 处；公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大影响的未公开重大信 息；公司近期经营情况正常，内外部经营环境未发生重大变化；公司、控股股东及实际控制人不存在关 于本公司的应披露而未披露的重大事项，或处于筹划阶段的重大事项；公司控股股东、实际控制人在股 票异常波动期间不存在买卖公司股票情形。 ...

1月5日，2026年A股第一个交易日，受到马斯克宣布脑机接口将量产消息的刺激，脑机接口概念板块多 只个股涨停，其中倍益康30cm涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通等十余只个 股20cm涨停，南京熊猫、亿嘉和等个股10cm涨停。 收盘至晚间，多家上市公司开始密集披露脑机接口相关进展，进一步点燃市场热情。 首先是亿嘉和，其在收盘后披露2025年12月份投资者关系活动中的内容，表示公司积极探索包括"脑机 接口"在内的前沿技术与具身智能机器人技术融合，并表示已与麦澜德签署战略合作协议，旨在共同探 索"脑机接口+具身智能机器人"技术在智能康养等场景的应用可能性。 2026年开年，A股市场的首个交易日，脑机接口概念板块成为最亮眼的明星。 1月6日，该板块延续前一日的热度，倍益康、美好医疗、三博脑科、岩山科技、南京熊猫、创新医疗等 多股竞价涨停，伟思医疗、爱朋医疗、熵基科技、翔宇医疗等高开超10%。 这场资本狂欢的导火索，来自特斯拉创始人埃隆·马斯克在2025年12月31日发布的重磅消息。当天马斯 克在社交媒体上宣布，其脑机接口公司Neuralink将于2026年"大规模生产"其脑机接口产品。而十几天 前 ...

今日， 被称作"杭州六小龙"之一的强脑科技被曝完成约20亿元融资，为脑机接口领域除马斯克旗下的Neuralink以外世界第二大规模融资。 以下文章来源于科创日报 ，作者张真 科创日报 . 科创圈都在关注的主流媒体，上海报业集团主管主办，《科创板日报》出品。 可孚医疗在互动平台表示，公司非常关注并看好脑机接口赛道，所以在早期以战略投资的方式进行布局。2025年底，公司投资力 之智能，持股比例12.45%。该公司致力于非侵入式脑机接口机器人等产品研发，未来有望与公司康复辅具类、呼吸支持类产品实现 战略协同。 开源证券1月6日研报表示，考虑到脑机接口目前处于商业化起步阶段，当前市场主要以主题投资风格为主，建议关注美股映射机遇和侵入式 脑机临床试验进度。从产业趋势上看，建议侵入式和非侵入式参考不同的标准，部分临床进展较快，神经调控等产品已经获批，非侵入式产 品商业化路径明确，规模化收入潜力可期。此外在软件、硬件（电极、芯片）及实验材料和设备（脑膜、DSA等）方面的脑机接口标的具有 稀缺性。 据悉，此次投资人阵容强大，包括著名投资机构IDG、由英特尔CEO陈立武创 立的华登国际，"果链"巨头蓝思科技、领益智造，战略投资 ...

证券日报网讯 1月6日，爱朋医疗（300753）发布公告称，公司股票于2026年1月5日、6日连续两个交易 日收盘涨幅偏离值累计超30%，属异常波动。公司核查后称前期披露无需更正，经营正常，无未披露重 大事项，控股股东及实控人期间未买卖股票。 ...

Group 1: Export Control Measures - The Ministry of Commerce of China has announced a ban on the export of all dual-use items to military users in Japan, as well as any other end-users that may enhance Japan's military capabilities, in accordance with the Export Control Law of the People's Republic of China [1] Group 2: Stock Market Performance - On January 6, the Shanghai Composite Index achieved a record of 13 consecutive days of gains, marking the longest streak in its history [2][9] - The index rose by 1.50% on January 6, with over 4,100 stocks increasing in value and a trading volume exceeding 2.8 trillion yuan [14] Group 3: Monetary Policy - The People's Bank of China emphasized the continuation of a moderately loose monetary policy during its work meeting held on January 5-6, aiming to enhance financial services for high-quality economic development and stabilize market expectations [4][11] Group 4: Market Sector Analysis - The brain-computer interface sector has seen significant growth, with multiple stocks reaching their daily limit up, including Sanbo Brain Science and Weisi Medical [14] - The non-ferrous metals and chemical sectors also performed strongly, with Zijin Mining's A-share market capitalization surpassing 100 billion yuan, achieving a historical high [14]

爱朋医疗公告，公司股票交易价格于2026年1月5日、2026年1月6日连续两个交易日内收盘价格涨幅偏离 值累计超过30%。公司前期披露的信息不存在需要更正、补充之处；公司未发现近期公共传媒报道了可 能或已经对本公司股票交易价格产生较大影响的未公开重大信息；公司近期经营情况正常，内外部经营 环境未发生重大变化；公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事项， 或处于筹划阶段的重大事项；公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票情 形。 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2026-001 江苏爱朋医疗科技股份有限公司 股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东及实际控制人不存在关于本公司的应披露而未披露的重大事 项，或处于筹划阶段的重大事项； 5、公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票情形。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所创业板股票上市规则》 等有关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等； 董事会也未获悉公司有根据《深圳证券交易所创业板股票上市规则》等有关规定应予 以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影响的信息；公司前 期披露的信息不存在需要更正、补充之处。 四、风 ...

Investment Rating - The investment rating for the brain-computer interface (BCI) industry is "Outperform the Market" (maintained) [1] Core Insights - The BCI industry is at a critical juncture of transitioning from technological breakthroughs to commercialization, driven by policies, technology advancements, and application scenarios. The global market is expected to experience explosive growth due to favorable policies, production expectations from companies like Neuralink, and clinical breakthroughs in China [3] - The report emphasizes focusing on core segments of the industry chain and technology routes, prioritizing companies with competitive advantages. Upstream, attention should be on hardware suppliers like EEG sensors and core chips; midstream, companies with key patents and clinical resources, especially in invasive technologies; and downstream, tracking companies that form commercial closed loops in rehabilitation and industrial control [3] Summary by Sections 1. Definition and Classification of BCI - BCI is defined as a direct communication link between brain electrical activity and external devices, used for reading or writing neural signals. It is categorized into invasive, semi-invasive, non-invasive, and interventional types [12][10] 2. Relevant Policies - The BCI industry is increasingly recognized in China, with policies like the "Implementation Opinions on Promoting the Innovation and Development of the BCI Industry" issued in July 2025, indicating a strategic focus on BCI as a national emerging industry [19][20] 3. Industry Overview - The BCI industry is transitioning from clinical trials to commercialization, with significant advancements in invasive BCI technologies led by companies like Neuralink. The report highlights the rapid development of non-invasive BCIs due to algorithm improvements and data accumulation [26][34] 4. Relevant Companies - Key players in the invasive BCI sector include Neuralink, which has conducted clinical trials and aims to decode language intentions by 2025. Other notable companies include Precision Neuroscience and Synchron, which are also making strides in the BCI field [46][49] 5. Investment Opportunities - The report identifies investment opportunities in companies that are developing BCI technologies across various applications, including rehabilitation, consumer electronics, and industrial safety. The focus is on companies that can navigate the regulatory landscape and demonstrate clinical efficacy [32][48]